Stem cell trial aims to regrow lungs in COPD patients
NCT ID NCT07355868
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests REGEND007, a stem cell therapy made from airway cells, in 12 people with COPD. The cells are given by IV infusion in increasing doses to see if they are safe and can help repair lung damage. The study is still recruiting and focuses on safety first.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGEND007 (airway basal layer stem cells)
What this could lead to
If it works, this could point toward a treatment that repairs lung tissue and improves breathing in COPD patients.
What could go wrong
This is a very early, small trial (12 people) focused on safety. It may not show clear benefit, and stem cell therapies carry risks like immune reactions or uncertain long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Zhejiang University School of Medicine
RECRUITINGYiwu, Zhejiang, 322000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••